Skip to main content

Table 5 The immunohistochemistry and gene mutation of T2 CRC patients

From: Identification of predictors for lymph node metastasis in T2 colorectal cancer: retrospective cohort study from a high-volume hospital

  

N0

N1/2

P-value

OR (95%CI)

Immunohistochemistry, n = 753

   

Ki67 a

 

80.00 (10.00)

80.00 (15.00)

0.226

 

MSH6 a

 

80.00 (10.00)

80.00 (10.00)

0.058

 

MSH2 a

 

82.00 (10.00)

84.00 (10.00)

0.038

1.029 (1.002–1.057)

PMS2 a

 

80.00 (10.00)

80.00 (15.00)

0.710

 

MLH1 a

 

80.00 (15.00)

80.00 (18.50)

0.435

 

HER2

   

0.870

 
 

1-

164 (78.8)

44 (21.2)

  
 

1+

269 (76.0)

85 (24.0)

  
 

2+

137 (77.4)

40 (22.6)

  
 

3+

10 (71.4)

4 (28.6)

  

HER1, n = 317

   

0.684

 
 

1-

22 (66.7)

11 (33.3)

  
 

1+

215 (77.3)

63 (22.7)

  
 

2+

2 (50.0)

2 (50.0)

  
 

3+

0

2 (100.0)

  

Gene mutation, n = 426

   

KRAS

   

0.227

 
 

No

175 (73.5)

63 (26.5)

  
 

Yes

148 (78.7)

40 (21.3)

  

BRAF

   

0.906

 
 

No

318 (75.9)

101 (24.1)

  
 

Yes

5 (71.4)

2 (28.6)

  

NRAS

   

0.913

 
 

No

308 (75.9)

98 (24.1)

  
 

Yes

15 (75.0)

5 (25.0)

  

PIK3CA

   

0.805

 
 

No

315 (75.7)

101 (24.3)

  
 

Yes

8 (80.0)

2 (20.0)

  
  1. a Values are presented as median (IQR)
  2. CRC, colorectal cancer
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us